Publications by authors named "Peter Bonate"

Claim this Profile
P
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug-Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors.
Mary P Choules, Yukio Otsuka, Jace C Nielsen, Megumi Iwai, Peter L Bonate

J Clin Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Akihiro Yamada, Jianning Yang, Peter L Bonate, Nakyo Heo, Srinivasu Poondru

Cancer Chemother Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.
Akihiro Yamada, Masato Takeuchi, Kanji Komatsu, Peter L Bonate, Srinivasu Poondru

Clin Transl Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Evaluation of CYP-Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers.
Megumi Iwai, Jace Nielsen, Mayuko Miyagawa, Melanie Patton, Peter L Bonate

J Clin Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sentinel Dosing-Time for a Risk-Based Approach?
Peter L Bonate, Mark Rogge, Jean-Michel Gries, Alexander J Prokopienko, Sudhakar M Pai

J Clin Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.
Akihiro Yamada, Mary P Choules, Frances A Brightman, Shigeru Takeshita, Shinsuke Nakao, Peter L Bonate

CPT Pharmacometrics Syst Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.
Peiying Zuo, Peter Bonate, Amit Garg, Maria Matsangou, Mei Tang

Clin Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine.
André Dallmann, Peter L Bonate, Janelle Burnham, Blessy George, Lynne Yao

CPT Pharmacometrics Syst Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Mary P Choules, Peiying Zuo, Yukio Otsuka, Amit Garg, Mei Tang, Peter Bonate

J Pharmacokinet Pharmacodyn· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective approaches to gene therapy computational modeling - spotlight on viral gene therapy.
Mary P Choules, Peter L Bonate, Nakyo Heo, Jared Weddell

J Pharmacokinet Pharmacodyn· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Mei Tang, Amit Garg, Peter L Bonate, Jonathan E Rosenberg, Maria Matsangou

Clin Pharmacokinet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Training the next generation of pharmacometric modelers: a multisector perspective.
Peter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, Richard Brundage, Brian Corrigan

J Pharmacokinet Pharmacodyn· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective.
Peter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, Richard Brundage, Brian Corrigan

J Pharmacokinet Pharmacodyn· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thoughts on plagiarism and the case against Claudine Gay.
Peter L Bonate

J Pharmacokinet Pharmacodyn· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACCP Position Statement on Hydration and Vitamin Infusion Clinics.
Peter L Bonate, Alexander J Prokopienko, Jean-Michel Gries,

J Clin Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Yukio Otsuka, Srinivasu Poondru, Peter L Bonate, Rachel H Rose, Masoud Jamei

J Pharmacokinet Pharmacodyn· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic comparability between two populations using nonlinear mixed effect models: a Monte Carlo study.
Siddhee A Sahasrabudhe, Peter L Bonate

J Pharmacokinet Pharmacodyn· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.
Ana Ruiz-Garcia, Paul Baverel, Dean Bottino, Michael Dolton, Yan Feng, Peter Bonate

J Pharmacokinet Pharmacodyn· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics.
Peter L Bonate

J Pharmacokinet Pharmacodyn· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of quantitative systems pharmacology in pharmacometrics and the scope of the journal.
Peter L Bonate

J Pharmacokinet Pharmacodyn· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Peter Bonate

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on training quantitative systems pharmacologists.
Tongli Zhang, Carolyn R Cho, Peter L Bonate

CPT Pharmacometrics Syst Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's note on the themed issue: integration of machine learning and quantitative systems pharmacology.
Peter L Bonate

J Pharmacokinet Pharmacodyn· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two heads are better than one: current landscape of integrating QSP and machine learning : An ISoP QSP SIG white paper by the working group on the integration of quantitative systems pharmacology and machine learning.
Tongli Zhang, Ioannis P Androulakis, Peter Bonate, Limei Cheng, Tomáš Helikar

J Pharmacokinet Pharmacodyn· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Peter Bonate

PLoS One· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis